Lv12
24 积分 2025-09-18 加入
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
55分钟前
待确认
Progress of pathology and genetics of histologic transformation in follicular lymphoma
1天前
已完结
Scientific white paper on concentration-QTc modeling
20天前
已完结
Erratum for the Research Article “Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15” by T. Han, M. Goralski, N. Gaskill, E. Capota, J. Kim, T. C. Ting, Y. Xie, N. S. Williams, D. Nijhawan
23天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
23天前
已完结
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)
25天前
已完结
Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide
26天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
皖公网安备34019202002308
